Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ron Paquette"'
Autor:
Srikanth Gajavelli, Loretta A. Williams, Mauricette Michallet, Ron Paquette, Irene DeGutis, Ruediger Hehlmann, Jorge E. Cortes, Teresa Zyczynski, Michael J. Mauro, Ginny P Sen, Carlo Gambacorti-Passerini, Bengt Simonsson, Stuart L. Goldberg
Publikováno v:
American Journal of Hematology
SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor (TKI) use and management patterns in patients with chronic phase‐chronic myeloid leukemia in the US and Europe in routine clinical practice. Herein we describe i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf757800bc84051386bb54526e10caf5
https://doi.org/10.1002/ajh.25306
https://doi.org/10.1002/ajh.25306
Autor:
Pascale Cony-Makhoul, Carlo Gambacorti-Passerini, Elza Lomaia, Ruediger Hehlmann, Bengt Simonsson, Michael J. Mauro, Aart Beeker, Mauricette Michallet, Eduardo Olavarria, Stuart L. Goldberg, Richard M. Hansen, Elisabetta Abruzzese, David Andorsky, Aimee Foreman, Jorge E. Cortes, Teresa Zyczynski, H. Jean Khoury, Ron Paquette
Publikováno v:
American Journal of Hematology
Achieving successful outcomes in chronic phase‐chronic myeloid leukemia (CP‐CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ad2e6a3c4d932c21654f5abea0ec46
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-339738
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-339738
Autor:
Martin Höglund, C. Michel Zwaan, Henrik Hjorth-Hansen, Rafael F. Duarte, Kimmo Porkka, Suhag Parikh, Benoit Brethon, Robert A. Wild, Satu Mustjoki, Håvar Knutsen, Tuija Lundán, Erkki Elonen, Hervé Dombret, Finella Brito-Babapulle, Hana Klamova, Lydia Eccersley, Montserrat Arnan, Roger Luo, Richard Smykla, Johanna Rimpiläinen, Franz Gruber, Ron Paquette, Emmanuel Raffoux, Perttu Koskenvesa, Francis Y. Lee
Publikováno v:
Blood, 112(4), 1005-1012. American Society of Hematology
Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome–positive (Ph+) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ceedc511a7965b3b88d994b5223378f
https://pure.eur.nl/en/publications/13a0aaaf-c56a-4ff5-893d-cc0e4742a4ad
https://pure.eur.nl/en/publications/13a0aaaf-c56a-4ff5-893d-cc0e4742a4ad
Autor:
Katharine Ellwood, Charles L. Sawyers, Nicholas C. Hsu, Mansoor Mohammed, P. Nagesh Rao, Ron Paquette, Mercedes E. Gorre
Publikováno v:
Science. 293:876-880
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4cf52ed46f9e61dd9406374af507a84
https://doi.org/10.1126/science.1062538
https://doi.org/10.1126/science.1062538
Autor:
Aimee Foreman, Carlo Gambacorti, Mauricette Michallet, Stuart L. Goldberg, Rüdiger Hehlmann, Ron Paquette, Bengt Simonsson, Yuanxin Rong, Jorge E. Cortes, Michael J. Mauro, Teresa Zyczynski, Aleksandra Zagorska, Brian Calimlim
Publikováno v:
Blood. 128:937-937
Introduction:SIMPLICITY (NCT01244750) is an ongoing observational study of CP-CML pts in routine clinical practice receiving first-line (1L) imatinib (IM) prior to 2010 (retrospective) or 1L IM, dasatinib (DAS) or nilotinib (NIL) since 2010 (prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e7b6e69b9408eb359d5bc9f3ca61a04
https://doi.org/10.1182/blood.v128.22.937.937
https://doi.org/10.1182/blood.v128.22.937.937
Autor:
Dario Greco, Leif Stenke, Agnès Guerci-Bresler, Philippe Rousselot, Jean Michel Cayuela, Ron Paquette, Satu Mustjoki, Kimmo Porkka, Ruth Seggewiss-Bernhardt, Anna Kreutzman, Teresa Melo, Francois-Xavier Mahon, Jukka Partanen, Henrik Hjorth-Hansen, Emmi Vakkila, Marja Ekblom, Jeffrey H. Lipton, Johan Richter, Alexis Talbot, Taina Jaatinen
Publikováno v:
Experimental hematology. 40(11)
Tyrosine kinase inhibitors have greatly improved the prognosis of chronic myeloid leukemia (CML). In addition to direct kinase inhibition, their effects can also be mediated through immune modulation, such as expansion of cytotoxic T and natural-kill
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb9c6699320bbaf629e8586fe83b9e0
https://pubmed.ncbi.nlm.nih.gov/22842045
https://pubmed.ncbi.nlm.nih.gov/22842045
Autor:
Ron Paquette, Guillermo Garcia-Manero, Dietmar Berger, Hagop M. Kantarjian, Janet Franklin, Eunice S. Wang, Francis J. Giles, Janice Gabrilove, Kuolung Hu, Peter L. Greenberg
Publikováno v:
Blood. 116(17)
We evaluated the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy. Forty patients with low- or intermediate-risk MDS were stratified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90cb77375857a3809ec73348109abc15
https://pubmed.ncbi.nlm.nih.gov/20631375
https://pubmed.ncbi.nlm.nih.gov/20631375
Autor:
Michael W. Deininger, Dietger Niederwieser, Byung Park, Douglas R. Smith, Michele Baccarani, Brian J. Druker, François Guilhot, Insa Gathmann, Thomas Fischer, Andreas Hochhaus, Richard Stone, John M. Goldman, Hagop M. Kantarjian, Jorge E. Cortes, Charlene So, Carlo Gambacorti-Passerini, Ron Paquette
Publikováno v:
Cancer. 110(7)
BACKGROUND. Clonal cytogenetic abnormalities (CCA) were detected in Philadelphia chromosome (Ph)-negative cells in some patients with chronic myeloid leukemia (CML) who attained a cytogenetic response to imatinib mesylate. In some patients, CCA/Ph-ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eeb0100423b54db18ca4823103bb561
https://pubmed.ncbi.nlm.nih.gov/17702093
https://pubmed.ncbi.nlm.nih.gov/17702093
Autor:
Moshe Talpaz, Hagop M. Kantarjian, Fei Huang, M. Anne Blackwood-Chirchir, Jorge E. Cortes, Charles L. Sawyers, Claude Nicaise, Eric Bleickardt, Arthur P. DeCillis, Neil P. Shah, Susan O'Brien, Tai-Tsang Chen, John Nicoll, Nicholas J. Donato, Ron Paquette, Vishwanath Iyer
Publikováno v:
The New England journal of medicine. 354(24)
Background The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome–positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fdc4e9976e295cf5740b617ac50af36
https://pubmed.ncbi.nlm.nih.gov/16960978
https://pubmed.ncbi.nlm.nih.gov/16960978
Autor:
Paul Bernard Coughlin, John Mascarenhas, Michael R. Savona, Moshe Talpaz, Jason Clark, Ronald Hoffman, Ron Paquette, Albert Assad, Lynda Foltz, Deborah S. Hunter, Robert Turner, Elliott F. Winton, Peter O'Neill, Srdan Verstovsek, Vikas Gupta
Publikováno v:
Blood. 124:714-714
Background: Janus kinases (JAKs), including JAK1 and JAK2, mediate the signaling of cytokines and growth factors implicated in the pathogenesis of myelofibrosis (MF). Suppression of JAK2 leads to cytopenias due to its involvement in the signaling pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::748a196314a31b069600603ec67ec2a8
https://doi.org/10.1182/blood.v124.21.714.714
https://doi.org/10.1182/blood.v124.21.714.714